Cargando…
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
INTRODUCTION: Most breast cancers that occur in women with germline BRCA1 mutations are estrogen receptor-negative (ER-) and also typically lack expression of progesterone receptor (PR) and HER2 overexpression. We undertook a study to assess the clinical factors that predict for an estrogen receptor...
Autores principales: | Tung, Nadine, Wang, Yihong, Collins, Laura C, Kaplan, Jennifer, Li, Hailun, Gelman, Rebecca, Comander, Amy H, Gallagher, Bridget, Fetten, Katharina, Krag, Karen, Stoeckert, Kathryn A, Legare, Robert D, Sgroi, Dennis, Ryan, Paula D, Garber, Judy E, Schnitt, Stuart J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880433/ https://www.ncbi.nlm.nih.gov/pubmed/20149218 http://dx.doi.org/10.1186/bcr2478 |
Ejemplares similares
-
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
por: Tung, Nadine, et al.
Publicado: (2010) -
BRCA1/2 testing: therapeutic implications for breast cancer management
por: Tung, Nadine M., et al.
Publicado: (2018) -
Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer
por: Tung, Nadine, et al.
Publicado: (2016) -
Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers
por: Song, Yun, et al.
Publicado: (2019) -
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)